DIVIS LABORATORIES
Back to Balance Sheet
|
DIVIS LABORATORIES Last 5 Year Total Non-Current Liabilities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Total Non-Current Liabilities | ₹1,215 Cr | ₹500 Cr | ₹611 Cr | ₹557 Cr | ₹437 Cr |
What is the latest Total Non-Current Liabilities ratio of DIVIS LABORATORIES ?
| Year | Total Non-Current Liabilities |
|---|---|
| Mar2026 | ₹1,215 Cr |
| Mar2025 | ₹500 Cr |
| Mar2024 | ₹611 Cr |
| Mar2023 | ₹557 Cr |
| Mar2022 | ₹437 Cr |
How is Total Non-Current Liabilities of DIVIS LABORATORIES Trending?
| Years | Total Non-Current Liabilities | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,215 Cr | 143.00 | |
| Mar2025 | ₹500 Cr | -18.17 | |
| Mar2024 | ₹611 Cr | 9.69 | |
| Mar2023 | ₹557 Cr | 27.60 | |
| Mar2022 | ₹437 Cr | - | |
Compare Total Non-Current Liabilities of peers of DIVIS LABORATORIES
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| DIVIS LABORATORIES | ₹305,051.5 Cr | 3.7% | 27.2% | 71.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹451,291.0 Cr | -1.8% | 7.6% | 11.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹177,333.0 Cr | -2.3% | 1.5% | 23.6% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹115,017.0 Cr | 0.6% | 13.4% | 15.7% | Stock Analytics | |
| CIPLA | ₹112,539.0 Cr | -1.3% | 6.1% | -6.9% | Stock Analytics | |
| MANKIND PHARMA | ₹109,622.0 Cr | 3% | 13.9% | 17.8% | Stock Analytics | |
DIVIS LABORATORIES Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| DIVIS LABORATORIES | 3.7% |
27.2% |
71.1% |
| SENSEX | 0.7% |
11.7% |
-2% |
You may also like the below Video Courses